logologo

Popular Boards

2 Mentions
Zhikai Zheng, Zong Yao, Yiyang Ma | Signal Transduction and Targeted Therapy | (2024)
Primary Link Pubmed DOI Openalex Full text (OA)

Abstract

The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is found primarily on the surfaces of various cell types within the human body. This receptor specifically interacts with GLP-1, a key hormone that plays an integral role in regulating blood glucose levels, lipid metabolism, and several other crucial biological functions. In recent years, GLP-1 medications have become a focal point in the medical community due to their innovative treatment mechanisms, significant therapeutic efficacy, and broad development prospects. This article thoroughly traces the developmental milestones of GLP-1 drugs, from their initial discovery to their clinical application, detailing the evolution of diverse GLP-1 medications along with their distinct pharmacological properties. Additionally, this paper explores the potential applications of GLP-1 receptor agonists (GLP-1RAs) in fields such as neuroprotection, anti-infection measures, the reduction of various types of inflammation, and the enhancement of cardiovascular function. It provides an in-depth assessment of the effectiveness of GLP-1RAs across multiple body systems-including the nervous, cardiovascular, musculoskeletal, and digestive systems. This includes integrating the latest clinical trial data and delving into potential signaling pathways and pharmacological mechanisms. The primary goal of this article is to emphasize the extensive benefits of using GLP-1RAs in treating a broad spectrum of diseases, such as obesity, cardiovascular diseases, non-alcoholic fatty liver disease (NAFLD), neurodegenerative diseases, musculoskeletal inflammation, and various forms of cancer. The ongoing development of new indications for GLP-1 drugs offers promising prospects for further expanding therapeutic interventions, showcasing their significant potential in the medical field.

Tags

Sample Definition And Size

The paper is a comprehensive review of GLP-1 receptor agonists (GLP-1RAs) and their therapeutic applications, integrating the latest clinical trial data and exploring potential signaling pathways and pharmacological mechanisms. It does not involve a specific study population or sample size, as it synthesizes information from multiple sources.

Study Type

Review article

Conflicts Of Interest

The authors declare no conflicts of interest.

Results Summary

The review highlights the extensive benefits of GLP-1RAs in treating a broad spectrum of diseases, including obesity, cardiovascular diseases, non-alcoholic fatty liver disease (NAFLD), neurodegenerative diseases, musculoskeletal inflammation, and various forms of cancer. It emphasizes the significant potential of GLP-1RAs in the medical field, showcasing their innovative treatment mechanisms, significant therapeutic efficacy, and broad development prospects.

Referenced In

William Fan
a year ago
William Fan's 2025 91 Day Weight Loss Challenge

GLP-1 Agonists, Ozempic, and Weight Loss

One major reason I started this challenge was to see whether I could lose weight at my age as or near as effective as people losing weight on GLP-1 Agonists like Ozempic, Wagovy, and Mounjaro. It felt like everywhere I looked, someone was trying these seemingly miracle cures and dropping a massive amount of weight, including people I knew personally.

I am generally apprehensive to try pharmaceuticals, especially ones that felt too new and too much of a miracle cure. But I read more about GLP-1 Agonists, I wanted to stay open minded about their value in the market and for health while also being clear eyed about the potential side effects.

As described in 'Glucagon-like peptide-1 receptor: mechanisms and advances in therapy' , GLP-1 is a naturally occurring hormone in the body that is usually secreted in response to nutrient intake. This hormone does a number of things, but primarily triggers hunger satiety. Semaglutides like the brands described above mimic this hormone and largely drive weight loss through appetite suppression. Although the drugs were originally created for people with type II diabetes, trials on obese and overweight populations showed these drugs were wildly effective for those adults as well. This study saw a mean weight loss of -14.9% vs -2.4% against placebo in 68 weeks.

The impact of these drugs seem remarkable and anecdotally people say it truly reduces the "food noise" for them. Alongside of the weight loss are significant benefits in cardiovascular health, skeletal muscle-related diseases, obesity management, and neurodegenerative conditions as described by Zhikai Zheng et al. Though it's not clear to me how much of these additional benefits are equivalent to other means of weight loss or reversal of metabolic diseases.

So my last major question is about the risks of these drugs? This meta-analysis of 23 studies showed the:

The meta-analysis revealed that the adverse event associated with semaglutide is gastrointestinal in nature (nausea and vomiting). No significant differences were observed between semaglutide and comparator groups...Semaglutide appears to have a favorable safety profile across diverse patient populations and treatment durations, supporting its continued use in the management of type 2 diabetes mellitus and obesity

I remain cautious as this drug still needs long term studies before we can draw conclusions on its long term impacts especially for non-diabetic individuals. However, at this point it does seem these drugs are as "miracle drug" as I've seen.

Read Full Post
1
William Fan
a year ago
Nutrition

GLP-1 Agonists, Ozempic, and Weight Loss

Repost from my 91 day challenge

One major reason I started this challenge was to see whether I could lose weight at my age as or near as effective as people losing weight on GLP-1 Agonists like Ozempic, Wagovy, and Mounjaro. It felt like everywhere I looked, someone was trying these seemingly miracle cures and dropping a massive amount of weight, including people I knew personally.

I am generally apprehensive to try pharmaceuticals, especially ones that felt too new and too much of a miracle cure. But I read more about GLP-1 Agonists, I wanted to stay open minded about their value in the market and for health while also being clear eyed about the potential side effects.

As described in Glucagon-like peptide-1 receptor: mechanisms and advances in therapy, GLP-1 is a naturally occurring hormone in the body that is usually secreted in response to nutrient intake. This hormone does a number of things, but primarily triggers hunger satiety. Semaglutides like the brands described above mimic this hormone and largely drive weight loss through appetite suppression. Although the drugs were originally created for people with type II diabetes, trials on obese and overweight populations showed these drugs were wildly effective for those adults as well. This study saw a mean weight loss of -14.9% vs -2.4% against placebo in 68 weeks.

The impact of these drugs seem remarkable and anecdotally people say it truly reduces the "food noise" for them. Alongside of the weight loss are significant benefits in cardiovascular health, skeletal muscle-related diseases, obesity management, and neurodegenerative conditions as described by Zhikai Zheng et al. Though it's not clear to me how much of these additional benefits are equivalent to other means of weight loss or reversal of metabolic diseases.

So my last major question is about the risks of these drugs? This meta-analysis of 23 studies showed the:

The meta-analysis revealed that the adverse event associated with semaglutide is gastrointestinal in nature (nausea and vomiting). No significant differences were observed between semaglutide and comparator groups...Semaglutide appears to have a favorable safety profile across diverse patient populations and treatment durations, supporting its continued use in the management of type 2 diabetes mellitus and obesity

I remain cautious as this drug still needs long term studies before we can draw conclusions on its long term impacts especially for non-diabetic individuals. However, at this point it does seem these drugs are as "miracle drug" as I've seen.

Read Full Post
4